Zenas BioPharma Inc. ZBIO 深 沪
等待开盘 08-06 09:30:00 美东时间
16.01
-0.800
-4.76%
华盛通- 最 高16.77
- 今 开16.77
- 成交量 4.07万股
- 最 低 16.00
- 昨 收 16.81
- 总市值 6.70亿
- 52周最高 26.2508
- 市盈率 静 --
- 换手率 0.10%
- 52周最低 5.83
- 委 比 -66.67%
- 总股本 4183.42万
- 历史最高 26.2508
- 量 比 0.72
- 振 幅 4.58%
- 历史最低 5.83
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zenas BioPharma, a clinical-stage biopharmaceutical company focused on autoimmune disease therapies, announced that on June 16, 2025, its Compensation Committee granted a non-qualified stock option to a newly hired employee. The option allows the purchase of 112,000 shares with an exercise price of $9.97 per share, equal to the closing price on the grant date. The shares will vest over four years, with 25% vesting after one year and the remainder...
06-20 20:15
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
<p>Zenas BioPharma, Inc. ("Zenas" or the "Company") (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that its management will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET. The presentation will be available live and as an archived replay on the Company’s website under "Investor & Media Relations." Zenas is dedicated to developing and commercializing ther...
05-29 11:05
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $30 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price target.
05-16 19:06
Zenas BioPharma Q1 EPS $(0.80) Beats $(1.05) Estimate, Sales $10.00M Beat $1.67M Estimate
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.05) by 23.81 percent. This is a 95.53 percent increase over losses of $(17.89) per share from
05-15 19:15
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zena...
04-18 04:20
Zenas BioPharma names Haley Laken as chief scientific officer
Zenas BioPharma (NASDAQ:ZBIO) said it has appointed Haley Laken as its chief scientific officer. Prior to joining the firm, Laken served as the chief operating officer at Tabby Therapeutics. More on Z...
04-07 19:29
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more t...
04-01 19:56
美股大行评级 | 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106863358302064640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 韦德布什：维持Astria Therapeutics(ATXS)"跑赢大市"评级，目标价从27美元升至28美元</p> <p>• HC Wainwright & Co.：维持LifeMD(LFMD)"买入"评级，目
03-13 09:38
Top-rated biotechs with negative enterprise values
After four consecutive years of underperformance, biotech stocks are among the most unloved segments in the market. Major industry benchmarks SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares Biotec...
03-02 03:28
